ATE225341T1 - In 6-position durch thio substituierte paclitaxele - Google Patents

In 6-position durch thio substituierte paclitaxele

Info

Publication number
ATE225341T1
ATE225341T1 AT97954044T AT97954044T ATE225341T1 AT E225341 T1 ATE225341 T1 AT E225341T1 AT 97954044 T AT97954044 T AT 97954044T AT 97954044 T AT97954044 T AT 97954044T AT E225341 T1 ATE225341 T1 AT E225341T1
Authority
AT
Austria
Prior art keywords
paclitaxele
thio
substituted
present
invention concerns
Prior art date
Application number
AT97954044T
Other languages
English (en)
Inventor
Andrew J Staab
John F Kadow
Dolatrai M Vyas
Mark D Wittman
Harold A Mastalerz
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE225341T1 publication Critical patent/ATE225341T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT97954044T 1996-12-24 1997-12-05 In 6-position durch thio substituierte paclitaxele ATE225341T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3341996P 1996-12-24 1996-12-24
US3635197P 1997-01-23 1997-01-23
PCT/US1997/022152 WO1998028288A1 (en) 1996-12-24 1997-12-05 6-thio-substituted paclitaxels

Publications (1)

Publication Number Publication Date
ATE225341T1 true ATE225341T1 (de) 2002-10-15

Family

ID=26709670

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97954044T ATE225341T1 (de) 1996-12-24 1997-12-05 In 6-position durch thio substituierte paclitaxele

Country Status (11)

Country Link
US (1) US5977386A (de)
EP (1) EP0960107B1 (de)
JP (1) JP2001507029A (de)
AT (1) ATE225341T1 (de)
AU (1) AU722684B2 (de)
CA (1) CA2268774A1 (de)
DE (1) DE69716135T2 (de)
DK (1) DK0960107T3 (de)
ES (1) ES2184149T3 (de)
PT (1) PT960107E (de)
WO (1) WO1998028288A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6362217B2 (en) 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
JP4975964B2 (ja) 2002-06-26 2012-07-11 メディゲーネ アクチエンゲゼルシャフト 脂肪親和性化合物から成る陽イオン性リポソームの製法
EP2390262A1 (de) 2003-05-16 2011-11-30 Intermune, Inc. Synthetische Chemokinrezeptorliganden und Verwendungsverfahren dafür
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060188508A1 (en) 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
MX2008011978A (es) 2006-03-22 2009-04-22 Medigene Ag Tratamiento del cancer de seno negativo al triple receptor.
PL217731B1 (pl) 2006-06-01 2014-08-29 Tomasz Byrski Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
EP2859916B1 (de) 2008-05-22 2017-11-29 Galera Labs, LLC Antimitotika mit Superoxid Dismutase Mimetika für die Kombinationstherapie gegen Krebs
US20110172293A1 (en) 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
CN102040570B (zh) * 2009-10-14 2014-07-30 江苏先声药物研究有限公司 硫代紫杉烷类衍生物及其制备方法和用途
EP3539563A1 (de) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Für cd22 spezifischer antikörper und verfahren zur verwendung davon
EP2916835A4 (de) 2012-11-12 2016-07-27 Redwood Bioscience Inc Verbindungen und verfahren zur herstellung eines konjugats
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
JP6745218B2 (ja) 2013-11-27 2020-08-26 レッドウッド バイオサイエンス, インコーポレイテッド ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
EP3107899B1 (de) 2014-02-19 2020-08-12 Aviv Therapeutics, Inc. Mitochondrial aldehyddehydrogenase 2 (aldh2)-bindende polycyclische amide und deren verwendung zur behandlung von krebs
CA2942101A1 (en) 2014-03-21 2015-09-24 Abbvie Inc. Anti-egfr antibodies and antibody drug conjugates
EP3373977A4 (de) 2015-11-12 2019-07-17 The Board of Trustees of the Leland Stanford Junior University Zellenpenetrierende, guanidiniumreiche oligophosphotriester zur wirkstoff- und sondenfreisetzung
WO2017087723A1 (en) 2015-11-19 2017-05-26 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
EP3231421A1 (de) 2016-04-11 2017-10-18 Greenaltech, S.L. Verwendungen eines carotenoids bei der behandlung oder prävention von durch stress verursachten störungen
EP3448885A4 (de) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC Antikörperkonjugate und verfahren zur herstellung und verwendung davon
PT3463308T (pt) 2016-06-01 2022-03-11 Servier Ip Uk Ltd Formulações de óxido de polialquileno asparaginase e métodos de fabrico e utilização do mesmo
EP3468993A1 (de) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3-antikörper und antikörperarzneimittelkonjugate
EP3468598A1 (de) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98-antikörper und antikörper-wirkstoff-konjugate
IL300274A (en) 2016-06-08 2023-04-01 Abbvie Inc Antibodies against B7–H3 and conjugates of drug and antibody
JP2019522643A (ja) 2016-06-08 2019-08-15 アッヴィ・インコーポレイテッド 抗cd98抗体及び抗体薬物コンジュゲート
BR112018075649A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
IL267902B1 (en) 2017-01-18 2025-09-01 F1 Oncology Inc Chimeric antigen receptors against axl or ror2 and methods of use thereof
EP3388082A1 (de) 2017-04-13 2018-10-17 Galera Labs, LLC Kombinationskrebsimmuntherapie mit makrocyclischem pentaaza-ringkomplex
CN118652192A (zh) 2017-05-24 2024-09-17 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
CN110003142A (zh) * 2018-01-04 2019-07-12 深圳福山生物科技有限公司 一种硒氰化合物及其用途
US20210338686A1 (en) 2018-01-31 2021-11-04 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
AU2019249221A1 (en) 2018-04-06 2020-10-22 The Regents Of The University Of California Methods of treating glioblastomas
EP3773632A4 (de) 2018-04-06 2022-05-18 The Regents of The University of California Verfahren zur behandlung von egfrviii-exprimierenden glioblastomen
KR20210009315A (ko) 2018-04-11 2021-01-26 오하이오 스테이트 이노베이션 파운데이션 안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물
WO2020018700A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
AU2020253449A1 (en) 2019-04-02 2021-11-18 William Robert ARATHOON Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
WO2021155028A1 (en) 2020-01-29 2021-08-05 Kenjockety Biotechnology, Inc. Anti-mdr1 antibodies and uses thereof
EP4161650A1 (de) 2020-06-04 2023-04-12 Kenjockety Biotechnology, Inc. Anti-abcg2-antikörper und verwendungen davon
EP4161564A1 (de) 2020-06-04 2023-04-12 Kenjockety Biotechnology, Inc. Multispezifische antikörper gegen abcg2-effluxpumpen-krebsantigen und zusammensetzungen, reagenzien, kits und verfahren im zusammenhang damit
KR20230061429A (ko) 2020-09-02 2023-05-08 켄조케티 바이오테크놀러지 인코포레이티드 항-abcc1 항체 및 이의 용도
EP4244257A1 (de) 2020-11-13 2023-09-20 Kenjockety Biotechnology, Inc. Anti-mrp4 (codiert durch abcc4-gen) antikörper und verwendungen davon
JP2023551203A (ja) 2020-11-20 2023-12-07 アール.ピー.シェーラー テクノロジーズ、エルエルシー 抗体-薬物コンジュゲートのためのグリコシド二重切断リンカー
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
KR20240116829A (ko) 2021-12-13 2024-07-30 윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 항-abcb1 항체
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en) * 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
DK0642503T3 (da) * 1991-09-23 2000-05-22 Bristol Myers Squibb Co 10-Desacetoxytaxolderivater
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US5352806A (en) * 1992-04-17 1994-10-04 Abbott Laboratories Taxol derivatives
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US5294637A (en) * 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
FR2697019B1 (fr) * 1992-10-15 1994-11-25 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
CA2109861C (en) * 1992-12-04 1999-03-16 Shu-Hui Chen 6,7-modified paclitaxels
CA2119261C (en) * 1992-12-23 2006-01-31 Michael A. Poss Novel sidechain-bearing taxanes and intermediates thereof
MX9308012A (es) * 1992-12-24 1994-08-31 Bristol Myers Squibb Co Eteres fosfonooximetilicos de derivados de taxano, solubles en agua y composiciones farmaceuticas que los incluyen.
DE69432140T2 (de) * 1993-03-05 2003-07-31 Florida State University, Tallahassee Verfahren zur Herstellung von 9-Desoxotaxanen
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
EP0982302B1 (de) * 1993-06-11 2004-04-14 PHARMACIA & UPJOHN COMPANY Delta 6,7-Taxol Derivate antineoplastische Verwendung und diese enthaltende pharmazeutische Zusammenstellungen
EP0764643A1 (de) * 1994-06-09 1997-03-26 Daiichi Pharmaceutical Co., Ltd. Deacetoxytaxol-derivate
DK0767786T3 (da) * 1994-06-28 1999-06-14 Upjohn Co 7-ether-taxol-analoge, antineoplastisk anvendelse deraf og farmaceutiske præparater indeholdende disse forbindelser
SK281526B6 (sk) * 1994-07-26 2001-04-09 Indena S. P. A. Semisyntetický taxán, spôsob jeho prípravy a medziprodukt, semisyntetický sekotaxán, spôsob jeho prípravy, farmaceutický prostriedok s ich obsahom a ich použitie

Also Published As

Publication number Publication date
US5977386A (en) 1999-11-02
WO1998028288A1 (en) 1998-07-02
DE69716135D1 (en) 2002-11-07
AU722684B2 (en) 2000-08-10
AU5792298A (en) 1998-07-17
CA2268774A1 (en) 1998-07-02
EP0960107A1 (de) 1999-12-01
PT960107E (pt) 2003-02-28
EP0960107A4 (de) 1999-12-01
JP2001507029A (ja) 2001-05-29
DK0960107T3 (da) 2003-02-10
DE69716135T2 (de) 2003-06-05
EP0960107B1 (de) 2002-10-02
ES2184149T3 (es) 2003-04-01

Similar Documents

Publication Publication Date Title
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
FI943749A0 (fi) Taksaanijohdannaisten fosfono-oksimetyylieetterit
FI954979A7 (fi) Kemoherkistävinä aineina käytettävät 10,11-metanodibentsosuberaanijohdannaiset
FI952248L (fi) Kasvainvastaisia koostumuksia, jotka sisältävät taksaanijohdannaisia
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
ES2181744T3 (es) Hidratos de paclitaxel cristalinos.
IL160051A0 (en) Ecteinascidin derivatives and pharmaceutical compositions containing the same
ATE231872T1 (de) Thiazolopyrimidinderivate
MX9601994A (es) Profarmacos de derivados de paclitaxel.
SE9802937D0 (sv) Novel compounds
CA2152771A1 (en) 7-o-ethers of taxane derivatives
ATE388960T1 (de) Glykopeptidderivate mit carboxysacchariden
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DZ1576A1 (fr) Compostions therapeutiques à base de dérives de 1,2-dithiole-3-thione.
ATE250340T1 (de) 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele
AU4558201A (en) Taxane anticancer agents
DE69107742D1 (de) Substituierte 3,7,9-Trioxa-1-aza-2,8-diphosphaspiro[4.5]dekane und stabilisierte Zusammensetzungen.
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
FI950101A7 (fi) 4-oksa-1-atsabisyklo 3,2,0 -7heptanoni-johdannaiset kasvainten vastaisina aineina
DE69202762D1 (de) 6,9-Bis(amino substituierte) Benzo(G)Phthalazin-5,10-Dionen als Antikrebs-mittel.
GR1001394B (el) Παράγωγα 4-[4-[4-(4-υδροξυφαινυλ)-1-πιπεραζινυλ] φαινυλ]-5-με?υλ3Η-1,2,4-τριαζολ-3-όνης.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0960107

Country of ref document: EP

REN Ceased due to non-payment of the annual fee